Literature DB >> 10654204

Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: influence of tidal volume.

E Mouloudi1, K Katsanoulas, M Anastasaki, S Hoing, D Georgopoulos.   

Abstract

OBJECTIVE: The delivery of bronchodilator drugs with metered-dose inhaler (MDI) and a spacer in mechanically ventilated patients has become a widespread practice. However, the various ventilator settings that influence the efficacy of MDI are not well established. The tidal volume (VT) during drug delivery has been suggested as one of the factors that might increase the effectiveness of this therapy. To test this, the effect of two different VT on the bronchodilation induced by beta 2-agonists administered with MDI and a spacer in a group of mechanically ventilated patients with chronic obstructive pulmonary disease (COPD) was examined.
METHODS: Nine patients with COPD, mechanically ventilated on volume-controlled mode, were prospectively randomised to receive six puffs of salbutamol (S, 100 micrograms/puff) either with a VT of 8 ml/kg (normal VT, 582 +/- 85) or with a VT of 12 ml/kg (high VT, 912 +/- 137). With both modes inspiratory flow was identical. S was administered with an MDI adapted to the inspiratory limb of the ventilator circuit using an aerosol cloud enhancer spacer. After a 6-h washout, patients were crossed-over to receive S by the alternative mode of administration. Static and dynamic airway pressures, minimum (Rint) and maximum (Rrs) inspiratory resistance, the difference between Rrs and Rint (delta R), static end-inspiratory respiratory system compliance (Cst,rs), intrinsic positive end-expiratory pressure (PEEPi) and heart rate (HR) were measured before and at 15, 30 and 60 min after S.
RESULTS: S caused a significant decrease in dynamic and static airway pressures, PEEPi, Rint and Rrs. These changes were not influenced by VT and were evident at 15, 30 and 60 min after S. With normal and high VT, Cst,rs, delta R and HR did not change after S.
CONCLUSIONS: We conclude that S delivered with an MDI and a spacer device induces significant bronchodilation in mechanically ventilated patients with COPD, the magnitude of which is not affected by at least a 50% increase in VT. These results do not support the VT manipulations when bronchodilators are administered in adequate doses during controlled mechanical ventilation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10654204     DOI: 10.1007/s001340051049

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  6 in total

Review 1.  Aerosol delivery via invasive ventilation: a narrative review.

Authors:  Hui-Ling Lin; James B Fink; Huiqing Ge
Journal:  Ann Transl Med       Date:  2021-04

2.  Aerosol therapy during mechanical ventilation: an international survey.

Authors:  Stephan Ehrmann; Ferran Roche-Campo; Giuseppe Francesco Sferrazza Papa; Daniel Isabey; Laurent Brochard; Gabriela Apiou-Sbirlea
Journal:  Intensive Care Med       Date:  2013-03-23       Impact factor: 17.440

3.  In vitro evaluation of aerosol bronchodilator delivery during mechanical ventilation: pressure-control vs. volume control ventilation.

Authors:  Dean R Hess; Christine Dillman; Robert M Kacmarek
Journal:  Intensive Care Med       Date:  2003-05-15       Impact factor: 17.440

Review 4.  Bronchodilator delivery with metered-dose inhaler during mechanical ventilation.

Authors:  D Georgopoulos; E Mouloudi; E Kondili; M Klimathianaki
Journal:  Crit Care       Date:  2000-07-11       Impact factor: 9.097

5.  Duration of salmeterol-induced bronchodilation in mechanically ventilated chronic obstructive pulmonary disease patients: a prospective clinical study.

Authors:  Polychronis Malliotakis; Manolis Linardakis; George Gavriilidis; Dimitris Georgopoulos
Journal:  Crit Care       Date:  2008-11-14       Impact factor: 9.097

Review 6.  Aerosol delivery during invasive mechanical ventilation: a systematic review.

Authors:  Jonathan Dugernier; Stephan Ehrmann; Thierry Sottiaux; Jean Roeseler; Xavier Wittebole; Thierry Dugernier; François Jamar; Pierre-François Laterre; Gregory Reychler
Journal:  Crit Care       Date:  2017-10-21       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.